Welcome to our dedicated page for Fibrobiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on Fibrobiologics stock.
FibroBiologics, Inc. (Nasdaq: FBLG) is a clinical-stage biotechnology company based in Houston that focuses on developing fibroblast-based therapies and fibroblast-derived materials for chronic diseases. News about FibroBiologics often centers on progress in its pipeline, intellectual property developments, and financing activities that support its research and clinical plans.
Company updates include announcements on preclinical and clinical milestones, such as HREC approval in Australia for a Phase 1/2 trial of CYWC628 in diabetic foot ulcers and the filing of a Phase 1/2 IND application with the U.S. FDA for CYPS317 in moderate to severe psoriasis. FibroBiologics also reports preclinical data for programs like CYMS101 for multiple sclerosis and FSdC spheroid therapies for degenerative disc disease, as well as work in bone marrow organoids for cancer and human longevity applications.
Investors following FBLG news will also see coverage of patent filings and intellectual property expansions, including a U.S. patent application for fibroblast-derived spheroids for cartilage and joint repair, and disclosures about the company’s portfolio of more than 270 issued and pending patents. Capital markets news features registered direct offerings, concurrent private placement warrants, and the use of a Standby Equity Purchase Agreement, along with updates on the payoff of outstanding convertible debt.
This news feed aggregates these types of developments in one place, from clinical and scientific updates to proxy statements, Nasdaq compliance notices, and financing transactions. Readers can use it to monitor FibroBiologics’ progress across its fibroblast-based platforms and to track regulatory, corporate, and capital markets events that may affect the FBLG stock.
FibroBiologics (Nasdaq: FBLG) closed a registered direct offering on Nov 19, 2025, selling 3,540,000 common shares and pre-funded warrants for 8,570,203 shares at $0.3303 per share/pre-funded warrant (less $0.00001 for each pre-funded warrant).
The purchase price was paid with sovereign .9999 fine gold coins valued at approximately $4,069.18 per ounce, producing gross proceeds of about $4.0 million before expenses. Pre-funded warrants are exercisable at $0.00001 and do not expire.
In a concurrent private placement the company issued unregistered warrants to buy up to 12,110,203 shares at an exercise price of $0.3303, exercisable following stockholder approval and expiring five years after that approval. The company plans to use net proceeds for general corporate purposes, including debt repayment.
FibroBiologics (Nasdaq: FBLG) announced a registered direct offering and concurrent private placement expected to close on or about November 19, 2025. The company agreed to sell 3,540,000 shares and pre-funded warrants to purchase 8,570,203 shares at $0.3303 per share/pre-funded warrant, with aggregate gross proceeds of approximately $4.0 million. Payment will be made in sovereign .9999 fine gold coins, which the company intends to liquidate to U.S. dollars. In the concurrent private placement, the company will issue unregistered warrants to purchase up to 12,110,203 shares at $0.3303, exercisable subject to stockholder approval and expiring five years after such approval.
The company intends to use net proceeds for general corporate purposes, including debt repayment.
FibroBiologics (Nasdaq: FBLG) reported Q3 2025 corporate updates and nine‑month results on Oct 31, 2025. Key program milestones target a Phase 1/2 trial of fibroblast‑based spheroid CYWC628 in diabetic foot ulcers with a planned initiation in Q1 2026 and completion in Q3 2026. The company completed IND‑enabling work for a psoriasis program and advanced a bone marrow organoid platform, plus a patent filing on multipotent cells from fibroblasts.
Financials: R&D rose to $6.6M (nine months) from $3.1M in 2024, G&A was $7.4M, net loss widened to $15.4M, and cash totaled $4.9M at Sept 30, 2025. Manufacturing runs and cGMP completion targeted by end‑2025. The company implemented cost reductions and plans IND submissions for psoriasis and multiple sclerosis programs.
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at Bio-Europe 2025 in Vienna, Austria, on November 4, 2025 at 4:15 p.m. CET.
The company said it will be available for one-on-one investor meetings during the conference (November 3–5, 2025) and that additional information is available via the company website or email at info@fibrobiologics.com. FibroBiologics focuses on therapeutics using fibroblasts and fibroblast-derived materials and holds 270+ patents issued and pending.
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at the 2025 ThinkEquity Conference on October 30, 2025 at the Mandarin Oriental, New York City. The company presentation is scheduled for 4:30 p.m. ET on October 30, and management will be available for one-on-one investor meetings throughout the event.
For presentation details or to request a meeting, contact the company via its website or email info@fibrobiologics.com.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company with over 270 patents, announced its participation in the 2025 Cell & Gene Meeting on the Mesa Conference. Chief Scientific Officer Dr. Hamid Khoja will present on October 7, 2025, at 2:15 p.m. MST in Phoenix, Arizona.
The company, which specializes in developing therapeutics using fibroblasts and fibroblast-derived materials, plans to initiate a clinical trial for diabetic foot ulcers in Q1 2026. The presentation will provide updates on their fibroblast-based technologies and their potential applications in treating various chronic diseases.
FibroBiologics (NASDAQ: FBLG) has published an opinion editorial highlighting the potential advantages of fibroblast cells over traditional stem cell therapies. The article, authored by CEO Pete O'Heeron and CSO Hamid Khoja, Ph.D., presents research supporting fibroblasts' superior characteristics including faster proliferation rates, better sourcing capabilities, and enhanced immune modulation properties.
The company's research focuses on treating chronic diseases such as multiple sclerosis, rheumatoid arthritis, and wound healing applications. With 270+ issued and pending patents, FibroBiologics positions fibroblast-based solutions as potentially superior to mesenchymal stem cells in terms of clinical utility, safety profile, and scalability.
FibroBiologics (NASDAQ:FBLG) has announced positive IND-enabling updates for its psoriasis treatment program using human dermal fibroblast (HDF) spheroids. The company reported that a single administration of HDF spheroids matched the efficacy of multiple doses of an anti-IL-23 monoclonal antibody in an acute psoriasis model, while also significantly reducing disease recurrence in a chronic-relapse model.
The biotechnology company, which holds over 270 patents issued and pending, is advancing its research through pilot studies focused on repeated dosing regimens, cytokine profiling, and histopathological assessments. The treatment targets psoriasis, an autoimmune condition affecting more than 8 million adults in the United States, with potential to address the broader chronic inflammatory disease market.
FibroBiologics (NASDAQ:FBLG) has announced significant progress in its Bone Marrow Organoid platform technology, showing promising potential for treating hematopoietic cancers and immune-related conditions. The company's pre-IND animal trials demonstrated that transplantation of these organoids significantly reduced tumor size in xenografted melanoma mouse models.
Key technological advantages include efficient ex vivo gene editing capabilities and the ability to cryopreserve the organoids for scalable treatment options. The platform shows potential for regenerating immune cell types, addressing age-related immune decline, and restoring immune function in compromised patients. Additionally, the technology could enable in-vivo generation of advanced cell therapies like CAR-T and CAR-NK cells directly within patients.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company focused on developing therapeutics using fibroblasts and fibroblast-derived materials, will participate in the H.C. Wainwright 27th Annual Global Investment Conference.
The company's CEO, Pete O'Heeron, will deliver a presentation on September 10 at 12:00 p.m. ET at the Lotte New York Palace Hotel. The company, which holds over 275 patents issued and pending, will also be available for one-on-one meetings with investors during the conference.